1
|
Belovezhets T, Kulemzin S, Volkova O, Najakshin A, Taranin A, Gorchakov A. Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties. Int J Mol Sci 2023; 24:ijms24043698. [PMID: 36835110 PMCID: PMC9966244 DOI: 10.3390/ijms24043698] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 01/28/2023] [Accepted: 02/10/2023] [Indexed: 02/15/2023] Open
Abstract
Over the past decade, CAR T cell therapy for patients with B cell malignancies has evolved from an experimental technique to a clinically feasible option. To date, four CAR T cell products specific for a B cell surface marker, CD19, have been approved by the FDA. Despite the spectacular rates of complete remission in r/r ALL and NHL patients, a significant proportion of patients still relapse, frequently with the CD19 low/negative tumor phenotype. To address this issue, additional B cell surface molecules such as CD20 were proposed as targets for CAR T cells. Here, we performed a side-by-side comparison of the activity of CD20-specific CAR T cells based on the antigen-recognition modules derived from the murine antibodies, 1F5 and Leu16, and from the human antibody, 2F2. Whereas CD20-specific CAR T cells differed from CD19-specific CAR T cells in terms of subpopulation composition and cytokine secretion, they displayed similar in vitro and in vivo potency.
Collapse
Affiliation(s)
| | - Sergey Kulemzin
- Almazov National Medical Research Centre, 197341 Saint Petersburg, Russia
| | - Olga Volkova
- Institute of Molecular and Cellular Biology of the SB RAS, 630090 Novosibirsk, Russia
| | - Alexander Najakshin
- Institute of Molecular and Cellular Biology of the SB RAS, 630090 Novosibirsk, Russia
| | - Alexander Taranin
- Institute of Molecular and Cellular Biology of the SB RAS, 630090 Novosibirsk, Russia
| | - Andrey Gorchakov
- Almazov National Medical Research Centre, 197341 Saint Petersburg, Russia
- Correspondence:
| |
Collapse
|
2
|
Chikaev A, Gorchakov A, Kulemzin S, Belovezhets T, Matvienko D, Volkova O, Taranin A. CAR-modified natural killer cell line expressing CD47/SIRPa blockers as a combined approach for solid cancer therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy485.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Sato E, Zaboronok A, Yamamoto T, Nakai K, Taskaev S, Volkova O, Mechetina L, Taranin A, Kanygin V, Isobe T, Mathis BJ, Matsumura A. Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. J Radiat Res 2018; 59:101-107. [PMID: 29281044 PMCID: PMC5950924 DOI: 10.1093/jrr/rrx071] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/05/2017] [Indexed: 06/07/2023]
Abstract
In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2-3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5-3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm-2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear-quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.
Collapse
Affiliation(s)
- Eisuke Sato
- Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
- Faculty of Health Sciences, Kyorin University, 5-4-1 Shimorenjaku, Mitaka, Tokyo, 181-8612, Japan
| | - Alexander Zaboronok
- Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Tetsuya Yamamoto
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 236-0004, Japan
| | - Kei Nakai
- Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Inashiki, Ibaraki, 300-0331, Japan
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Lavrentieva prosp.11, Novosibirsk, 630090, Russian Federation
- Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russian Federation
| | - Olga Volkova
- Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russian Federation
- Institute of Molecular and Cell Biology, Lavrentieva prosp.8/2, Novosibirsk, 630090, Russian Federation
| | - Ludmila Mechetina
- Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russian Federation
- Institute of Molecular and Cell Biology, Lavrentieva prosp.8/2, Novosibirsk, 630090, Russian Federation
| | - Alexander Taranin
- Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russian Federation
- Institute of Molecular and Cell Biology, Lavrentieva prosp.8/2, Novosibirsk, 630090, Russian Federation
| | - Vladimir Kanygin
- Budker Institute of Nuclear Physics, Lavrentieva prosp.11, Novosibirsk, 630090, Russian Federation
- Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russian Federation
- Novosibirsk State Medical University, Krasny prosp. 52, Novosibirsk, 630091, Russian Federation
| | - Tomonori Isobe
- Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Bryan J Mathis
- Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Akira Matsumura
- Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| |
Collapse
|
4
|
Reshetnikova E, Guselnikov S, Volkova O, Baranov K, Taranin A, Mechetina L. B cell-specific protein FCRLA is expressed by plasmacytoid dendritic cells in humans. Cytometry B Clin Cytom 2018; 94:683-687. [PMID: 29236355 DOI: 10.1002/cyto.b.21611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 11/14/2017] [Accepted: 12/11/2017] [Indexed: 11/11/2022]
Abstract
BACKGROUND Fc receptor-like A (FCRLA) is a unique member of a family of Fc receptor like-molecules that lacks a transmembrane region and is an ER-resident protein. In mice and humans, FCRLA has been known as a B cell specific protein. We report here that, in humans, FCRLA is also expressed in a subpopulation of plasmacytoid dendritic cells (pDCs). METHODS Human peripheral blood mononuclear cells (PBMC), splenocytes, and tonsillar cells were stained for lineage markers followed by fixation/saponin permeabilization and intracellular staining for FCRLA, and then analyzed by flow cytometry with CD123 and CD303 used as pDC markers. RESULTS We conducted an extensive flow cytometric analysis of a rare population of CD19-FCRLA+ cells found for the first time in human lymphoid tissues that we assigned to pDCs as they were lin-/CD123+/CD303+. FCRLA expression in human pDCs was further confirmed by the RT-PCR analysis of cDNA of pDCs isolated from the peripheral blood of a healthy donor. FCRLA-positive pDCs expressed a lower level of HLA-DR than their FCRLA-negative counterparts. CONCLUSIONS FCRLA has long been viewed as a B cell specific protein, and this is the first time its expression has also been shown in human pDCs. © 2017 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Evdokiya Reshetnikova
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Sergey Guselnikov
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.,Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia
| | - Olga Volkova
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Konstantin Baranov
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Alexander Taranin
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.,Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia
| | - Ludmila Mechetina
- Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.,Department of Natural Sciences, Novosibirsk State University, Novosibirsk, Russia
| |
Collapse
|
5
|
Koval O, Volkova O, Kulemzin S, Gorchakov A, Tkachenko A, Nushtaeva A, Kuligina E, Richter V, Taranin A. NK-cell based delivery of anticancer therapeutics. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Volkova O, Guselnikov S, Mechetina L, Chikaev N, Baranov K, Kulemzin S, Reshetnikova E, Najakshin A, Taranin A. Development and characterization of domain-specific monoclonal antibodies produced against human SLAMF9. Monoclon Antib Immunodiagn Immunother 2015; 33:209-14. [PMID: 25170999 DOI: 10.1089/mab.2014.0010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
SLAMF9 is a member of the signaling lymphocyte-activating molecule (SLAM) immunoreceptor family. The SLAM family receptors are expressed in a broad range of immune cells and play an important role in immunity. To date, SLAMF9 is the least studied member of this family. Its ligand, signaling properties, and cells on whose surface it is expressed are unknown. We generated hybridoma clones 6E11 and 7G5 secreting monoclonal antibodies specific to human SLAMF9. BALB/c mice were immunized with Escherichia coli-expressed purified SLAMF9 protein; splenocytes from these mice were fused with mouse myeloma cell line NS-1. Based on isotyping of the MAbs, clone 6E11 was referred to the IgG1 subclass, while 7G5 to IgG2b. The specificity of these MAbs was assessed by ELISA, immunoblotting, immunohistochemistry, and flow cytometry. According to the results of epitope analysis, clone 6E11 reacts with the C2-like domain, whereas 7G5 is specific to the V-like domain of the SLAMF9 molecule. The generated MAbs were demonstrated to be applicable in various immunochemical analyses. They may be useful tools in studies clarifying the expression and function of human SLAMF9.
Collapse
Affiliation(s)
- Olga Volkova
- 1 Institute of Molecular and Cellular Biology , Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Kulemzin S, Chikaev N, Volkova O, Reshetnikova E, Taranin A, Najakshin A, Mechetina L. Characterization of human FCRLA isoforms. Immunol Lett 2013; 152:153-8. [PMID: 23742757 DOI: 10.1016/j.imlet.2013.05.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Revised: 05/20/2013] [Accepted: 05/26/2013] [Indexed: 02/01/2023]
Abstract
FCRLA is an ER-resident B-cell specific protein. The exact function of this protein remains unclear although human FCRLA has been recently shown to interact with IgM, IgG and IgA. The retention of FCRLA in ER is mediated by the N-terminal domain. The major human FCRLA isoform is encoded by five exons, of which one encodes a short signal peptide (SSP) and the others code four protein domains. Here we show that human tissues also produce transcripts which contain an additional exon and encode proteins with signal peptide that is six residues longer (LSP). Transfection experiments demonstrated that the extension of the signal peptide had no visible effect on the topology and molecular mass of the processed four-domain FCRLA isoform. However, the length of the signal peptide was found to affect processing of two-domain FCRLA isoforms composed of the third and fourth domains (FCRLAd2). The signal peptide was not cleaved in the SSP-FCRLAd2 and this isoform was found to accumulate in the ER. In contrast, the LSP-containing FCRLAd2 isoform was processed, O-glycosylated and secreted. The secreted FCRLAd2 isoform did not interact with IgG- or IgM-immunosorbents.
Collapse
Affiliation(s)
- Sergey Kulemzin
- Institute of Molecular and Cellular Biology SB RAS, 8 Lavrentiev Avenue, Novosibirsk 630090, Russia
| | | | | | | | | | | | | |
Collapse
|
8
|
Burrows P, Santiago T, Kulemzin S, Reshetnikova E, Chikaev N, Volkova O, Mechetina L, Zhao M, Davis R, Taranin A, Najakshin A, Hendershot L. FCRLA is an intracellular FcR-related protein that binds IgM, IgG and IgA isotypes in B cells (45.11). The Journal of Immunology 2011. [DOI: 10.4049/jimmunol.186.supp.45.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Fc-receptor-like A (FCRLA) is a novel member of the extended Fc receptor (FcR) family. Unlike the classical FcRs and Fc receptor-like (FCRL) molecules, which are typically transmembrane receptors with extracellular ligand binding domains, FCRLA has no predicted transmembrane domain or N-linked glycosylation sites and is positioned intracellularly. We show by confocal microscopy and biochemical assays that FCRLA is a soluble, resident ER protein; however, it lacks a characteristic KDEL retention sequence at its C-terminus. Using a series of deletion mutants, we found that its ER retention is most likely mediated by the amino terminal domain. We have also recently identified ER localized immunoglobulin as an FCRLA ligand. These results indicate that FCRLA is unique among the large FcR family in that can associate with multiple immunoglobulin isotypes, including IgM, IgG, and IgA. To better understand the role of this protein in human disease, B cell chronic lymphocytic leukemia (CLL) samples were assayed for FCRLA expression by flow cytometry. Interestingly, the receptor was more highly expressed by the indolent form of CLL, which is distinguished by somatically hypermutated heavy chain variable region genes, than by the aggressive high-risk form, which features more germline B cell receptor characteristics. These results indicate that FCRLA may thus be a useful diagnostic marker for CLL.
Collapse
Affiliation(s)
- Peter Burrows
- 1Microbiology, University of Alabama at Birmingham, Birmingham, AL
| | - Teresa Santiago
- 1Microbiology, University of Alabama at Birmingham, Birmingham, AL
| | - Sergei Kulemzin
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Evdokia Reshetnikova
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Nikolai Chikaev
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Olga Volkova
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Ludmila Mechetina
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Meina Zhao
- 1Microbiology, University of Alabama at Birmingham, Birmingham, AL
| | - Randall Davis
- 1Microbiology, University of Alabama at Birmingham, Birmingham, AL
| | - Alexander Taranin
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | - Alexander Najakshin
- 2Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation
| | | |
Collapse
|
9
|
Baranov K, Volkova O, Chikaev N, Mechetina L, Laktionov P, Najakshin A, Taranin A. A direct antigen-binding assay for detection of antibodies against native epitopes using alkaline phosphatase-tagged proteins. J Immunol Methods 2008; 332:73-81. [DOI: 10.1016/j.jim.2007.12.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2007] [Revised: 12/13/2007] [Accepted: 12/19/2007] [Indexed: 11/15/2022]
|